

Special Issue

Avian Influenza Virus: New Strategies to Elicit Immune Responses and to Prevent and Control Infection

Message from the Guest Editor

Avian influenza virus infection (AIV) has spread worldwide spread, and is a highly contagious. AIV infection is one of the greatest causes for recent concerns to public health and the economy worldwide. AIV has been considered to be one of the most high-priority pathogens and an economically important poultry virus. Despite the extensive research in recent decades to improve vaccine efficacies, surveillance methods, and biosecurity measures to control viral respiratory infections in poultry, recent outbreaks of AIVs have provoked notable concerns about the available measures and resources for controlling the spread of the virus and preventing disease. Due to the importance of public health concerns of avian influenza virus and its potential economic consequences, we would like to present this Special Issue documenting the recent progress in understanding of host–virus interactions and research efforts focused on developing effective vaccines and prophylactic strategies as well as novel approaches to tailor favorable host antiviral responses to control diseases that are caused by AIV.

Guest Editor

Dr. Neda Barjesteh

Department of Pathology and Microbiology, Faculty of Veterinary Medicine, University of Montreal, Montreal, Canada

Deadline for manuscript submissions

closed (31 July 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/40961

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).